Molecular basis of obesity and the risk for cardiovascular disease

Herz

Volumn 31, Issue 3, 2006, Pages 200-206

  Soufi, Muhidien ^a   Sattler, Alexander M ^a   Herzum, Matthias ^a   Maisch, Bernhard ^a   Schaefer, Jürgen R ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Cardiovascular risk factors; Gene variants; Lipids; Metabolic syndrome; Obesity

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA TOCOPHEROL; CONTRACEPTIVE AGENT; DIGOXIN; ERYTHROMYCIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOAMINE OXIDASE INHIBITOR; RETINOL; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; VITAMIN D; VITAMIN K GROUP;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSLIPIDEMIA; EUROPE; FECES INCONTINENCE; GALLSTONE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INTESTINAL CRAMP; METABOLIC DISORDER; NEPHROLITHIASIS; NEUROTOXICITY; OBESITY; OILY SPOTTING; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT; UNITED STATES; VALVULAR HEART DISEASE;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; MODELS, BIOLOGICAL; OBESITY; RISK ASSESSMENT; RISK FACTORS;

EID: 33745144337     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2801-2     Document Type: Review

References (58)

1. World Health Organization. The World Health Report 2001 annex Table 2. Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2000. Geneva: World Health Organization, 2001 (http://www.who.int/whr/2001/main/en/ annex/annex2.htm).
2. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
3. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
4. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001;104:503-16.
5. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-43.
6. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, 3-5 June, 1997. WHO TRS 894. Geneva: World Health Organization, 1998.
7. Moyad MA. Current methods used for defining, measuring, and treating obesity. Semin Urol Oncol 2001;19:247-56.
8. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 2005;162:101-14.
9. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
10. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. Circulation 2005;112:2735-52.
11. Yusuf S, Hawken S, Ôunpuu S, on behalf of the INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9.
12. Gill H, Mugo M, Whaley-Connell A, et al. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci 2005;330:290-4.
13. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002;10:97S-104S.
14. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
15. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004;20:295-304.
16. Loktionov A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases. J Nutr Biochem 2003;14:426-51.
17. Swinburn BA, Caterson I, Seidell JC, et al. Diet, nutrition and the prevention of excess weight gain and obesity. Public Health Nutr 2004;7:123-46.
18. Blundell JE, Cooling J. Routes to obesity: phenotypes, food choices and activity. Br J Nutr 2000;83:Suppl 1:S33-8.
19. Clark DO. Physical activity efficacy and effectiveness among older adults and minorities. Diabetes Care 1997;20:1176-82.
20. Savage PJ, Harlan WR. Racial and ethnic diversity in obesity and other risk factors for cardiovascular disease: implications for studies and treatment. Ethn Dis 1991;1:200-11.
21. Jequier E, Tappy L. Regulation of body weight in humans. Physiol Rev 1999;79:451-80.
22. Matsunami H, Montmayeur J-P, Buck LB. A family of candidate taste receptors in human and mouse. Nature 2000;404:601-4.
23. McMinn JE, Baskin DG, Schwartz MW. Neuroendocrine mechanisms regulatingfood intake and body weight. Obes Rev 2000;1:37-46.
24. Ueda T, Ugawa S, Ishida Y, et al. Identification of coding single-nucleotide polymorphisms in human taste receptor genes involving bitter tasting. Biochem Biophys Res Commun 2001;285:147-51.
25. Zhang YY, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
26. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002;967:379-88.
27. Houseknecht KL, Baile CA, Matteri RL, et al. The biology of leptin: a review. J Anim Sci 1998;76:1405-20.
28. Houseknecht KL, Portocarrero CP. Leptin and its receptors: regulators of whole-body energy homeostasis. Domest Anim Endocrinol 1998;15:457-75.
29. Seckl JR, Morton NM, Chapman KE, et al. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004;59:359-93.
30. Li WD, Reed DR, Lee JH, et al. Sequence variants in the 5′ flanking region of the leptin gene are associated with obesity in women. Ann Hum Genet 1999;63:227-34.
31. Mammes O, Betoulle D, Aubert R, et al. Association of the G-2548A polymorphism in the 5′ region of the LEP gene with overweight. Ann Hum Genet 2000;64:391-4.
32. Cohen P, Friedman JM. Leptin and the control of metabolism: role for stearoyl-CoA desaturase-1 (SCD-1). J Nutr 2004;134:2455-63.
33. Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 2005;6:169-74.
34. Peeters TL. Ghrelin: a new player in the control of gastrointestinal functions. Gut 2005;54:1638-49.
35. Horvath TL, Diano S, Sotonyi P, et al. Minireview: Ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 2001;142:4163-9.
36. Liddle RA. Regulation of cholecystokinin secretion in humans. J Gastroenterol 2000;35:181-7.
37. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 2002;418:650-4.
38. Ukkola O, Ravussin E, Jacobson P, et al. Role of ghrelin polymorphisms in obesity based on three different studies. Obes Res 2001;10:782-91.
39. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
40. Funahashi T, Nakamura T, Shimomura I, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999;38:202-6.
41. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-32.
42. Okamoto Y, Arita Y, Nishida M, et al. An adiopocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000;32:47-50.
43. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
44. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-9.
45. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
46. Hotamisligil GS. The role of TNFα and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5.
47. Kamboh MI, Bunker CH, Aston CE, et al. Genetic association of five apolipoprotein polymorphisms with serum lipoprotein-lipid levels in African blacks. Genet Epidemiol 1999;16:205-22.
48. Okubo M, Horinishi A, Kim DH, et al. Seven novel sequence variants in the human low density lipoprotein receptor related protein 5 (LPR5) gene. Hum Mutat 2002;19:186.
49. Song J, Hong SH, Min W, et al. Association between triglyceride-rich lipoprotein remnant receptor polymorphisms and lipid traits. Clin Biochem 2000;33:441-7.
50. Eckel RH, Yost TJ, Jensen DR. Alterations in lipoprotein lipase in insulin resistance. Int J Obes Relat Metab Disord 1995;19:S16-21.
51. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
52. Puchois P, Kandoussi A, Fievet JT, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987;68:35-40.
53. Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1819-28.
54. Cominacini L, Garbin U, Davoli A, et al. High-density lipoprotein cholesterol concentrations and postheparin hepatic and lipoprotein lipases in obesity: relationships with plasma insulin levels. Ann Nutr Metab 1993;37:175-84.
55. Huang Y, Eckardstein A von, Wu S, et al. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995;15:1412-8.
56. Lamarche B, Moorjani S, Cantin B, et al. Associations of HDL 2 and HDL 3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997;17:1098-105.
57. Hurt-Camejo E, Olsson U, Wiklund O, et al. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997;17:1011-7.
58. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750-4.